Climate Change Position Statement
Amgen recognizes the connection between environmental stresses and health as reported by the World Health Organization.1 The Intergovernmental Panel on Climate Change, a United Nations body responsible for assessing the science related to climate change, has also concluded that climate change directly affects human health as it threatens global air quality,2 water availability,3 and food security,4 and affecting the frequency of infectious,5 respiratory, and cardiovascular diseases.6
Amgen's latest environmental sustainability goals include a target of achieving carbon neutrality in our operations by 20277 and are aligned with the Paris Agreement's long-term goal of limiting global warming to 1.5 degrees Celsius, as compared to pre-industrial levels.8
The Amgen Board of Directors and its applicable committees oversee Amgen's Environmental, Social and Governance (ESG) strategy. Amgen's executive management updates the Board and its committees regarding the status and progress of the Company's ESG activities.
Achieving Science-Based Targets
Our latest environmental sustainability goals include the following 2027 targets:7,9
- Achieve carbon neutrality for Amgen-owned and operated facilities and operations
- Reduce water consumption by 40% from a 2019 baseline
- Reduce waste disposed by 75% from a 2019 baseline
Amgen's 2027 carbon emissions targets have been approved by the Science Based Targets initiative (SBTi) and are consistent with the goal of limiting global warming to 1.5 degrees Celsius for Scope 1 and 2 emissions. We also established an SBTi Scope 3 supplier engagement target to engage with 73% of our suppliers by spend in key categories to support their adoption of science-based carbon reduction targets by 2027. In 2019, this comprised 67% of our Scope 3 emissions. For more on our SBTi approval please click here.
Dedication to Innovation
Amgen Ecovation™ is our approach to innovative and sustainable manufacturing, which we embed into the upfront design, development and execution of all new laboratory, manufacturing and administrative buildings.
As part of our SBTi targets, we are engaging with our suppliers to assist and encourage carbon reduction throughout our value chain, including by developing training, tools, and participating in collaboration alliances to help encourage our suppliers to reduce their global carbon dioxide emissions.
Amgen is also partnering with our peers and recently joined Schneider Electric's Energize program to support the decarbonization of the pharmaceutical supply chain. The Energize press release can be found here.
Additionally, Amgen's Supplier Sustainability Program is designed to monitor our most strategic suppliers' sustainability performance in four areas, including business ethics, labor and human rights, sustainable procurement and environmental impacts, as outlined in our Supplier Code of Conduct available here.
Monitoring and Reporting on our Performance
Amgen has established a comprehensive carbon reduction strategy comprised of innovation, efficiency, and renewable energy to achieve our 2027 carbon neutrality target.7 We use a centralized environmental management system to track, monitor, and assess the performance of our sites and benchmark our progress.
We have also developed a range of external disclosures to communicate on our ESG performance and have reported to the CDP since 2010.
For more on our environmental sustainability program, please see our Responsibility section
As of April 18, 2023
- https://www.ipcc.ch/report/ar6/wg1/downloads/faqs/IPCC_AR6_WGI_FAQ_Chapter_06.pdf PAGE: 5/6
- https://www.ipcc.ch/report/ar6/wg1/downloads/report/IPCC_AR6_WGI_Chapter08.pdf PAGE: 6/156
- https://www.ipcc.ch/srccl/chapter/summary-for-policymakers/ SECTION (A.2)
- https://www.ipcc.ch/report/ar6/wg1/downloads/report/IPCC_AR6_WGI_Chapter01.pdf PAGE 92/142 (Figure 1.27)
- Carbon neutrality goal refers to Scope 1 and 2. Reductions take into account only verified reduction projections and do not take into account changes associated with the contraction or expansion of the Company.